Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control / Afzal Hussain, Sima Singh, Sabya Sachi Das, Keshireddy Anjireddy, Subramanian Karpagam, Faiyaz Shakeel
In spite of advances in tuberculosis (TB) chemotherapy, TB is still airborne deadly disorder as a major issue of health concern worldwide today. Extensive researches have been focused to develop novel drug delivery systems to shorten the lengthy therapy approaches, prevention of relapses, reducing dose-related toxicities and to rectify technologically related drawbacks of anti-tubercular drugs. Moreover, the rapid emergence of drug resistance, poor patient compliance due to negative therapeutic outcomes and intracellular survival of Mycobacterium highlighted to develop carrier with optimum effectiveness of the anti-tubercular drugs. This could be achieved by targeting and concentrating the drug on the infection reservoir of Mycobacterium. In this article, we briefly compiled the general aspects of Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery carrier system to enhance therapeutic effects of drug and the high level of patient compliance. Recently developed several vaccines might be shortly available as reported by WHO.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Current drug delivery - 16(2019), 5, Seite 400- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hussain, Afzal [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (30 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL009010149 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL009010149 | ||
| 003 | DE-627 | ||
| 005 | 20231129070646.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220323s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL009010149 | ||
| 035 | |a (KFL)prod_DARH_.535EF6B52E2A9E15207D4C9BFB2380780310EE56 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Hussain, Afzal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control |c Afzal Hussain, Sima Singh, Sabya Sachi Das, Keshireddy Anjireddy, Subramanian Karpagam, Faiyaz Shakeel |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (30 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In spite of advances in tuberculosis (TB) chemotherapy, TB is still airborne deadly disorder as a major issue of health concern worldwide today. Extensive researches have been focused to develop novel drug delivery systems to shorten the lengthy therapy approaches, prevention of relapses, reducing dose-related toxicities and to rectify technologically related drawbacks of anti-tubercular drugs. Moreover, the rapid emergence of drug resistance, poor patient compliance due to negative therapeutic outcomes and intracellular survival of Mycobacterium highlighted to develop carrier with optimum effectiveness of the anti-tubercular drugs. This could be achieved by targeting and concentrating the drug on the infection reservoir of Mycobacterium. In this article, we briefly compiled the general aspects of Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery carrier system to enhance therapeutic effects of drug and the high level of patient compliance. Recently developed several vaccines might be shortly available as reported by WHO | ||
| 700 | 1 | |a Singh, Sima |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Sabya Sachi |e verfasserin |4 aut | |
| 700 | 1 | |a Anjireddy, Keshireddy |e verfasserin |4 aut | |
| 700 | 1 | |a Karpagam, Subramanian |e verfasserin |4 aut | |
| 700 | 1 | |a Shakeel, Faiyaz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug delivery |d Bussum [u.a.] : Bentham Science Publ., 2004 |g 16(2019), 5, Seite 400- |h Online-Ressource |w (DE-627)KFL000006416 |w (DE-600)2155966-1 |w (DE-576)273889680 |x 1875-5704 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2019 |g number:5 |g pages:400- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1567-2018&volume=16&issue=5&spage=400 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_01 | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2019 |e 5 |h 400- | ||